Blood centres across India that fail mandatory quality audits could soon be barred from carrying out routine testing until they identify the cause of the failure and correct it, according to proposals submitted to the country's top drug-regulatory advisory body.

The proposal, reported from New Delhi, would apply to blood centres nationwide and is linked to mandatory quality audits. Under the plan, a centre that does not clear the audit would not be allowed to conduct routine testing until it has established what went wrong and taken steps to fix it.

The details come from proposals placed before the apex drug-regulatory advisory body. The original report did not specify which body is considering the proposals, the timeline for a decision, or the penalties that would apply.

The move, as described in the proposals, is aimed at tying a blood centre's permission to continue routine testing to the outcome of its mandatory quality audit. No further particulars, including the identity of the centres concerned or the number of audits involved, were provided.